Genmab A/S GMAB 深 沪
等待开盘 12-20 09:30:00 美东时间
32.365
+0.865
+2.75%
华盛通- 最 高32.80
- 今 开32.13
- 成交量 259.36万股
- 最 低 30.81
- 昨 收 31.50
- 总市值 211.99亿
- 52周最高 33.65
- 市盈率 静 44.72
- 换手率 0.40%
- 52周最低 17.235
- 委 比 1.30%
- 总股本 6.55亿
- 历史最高 49.07
- 量 比 1.92
- 振 幅 6.32%
- 历史最低 1.10
- 每 手 1
- 风险率 4.47%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Bristol Myers' Cancer Breakthrough Breyanzi Just Won Its Fifth FDA Approval
FDA approves Breyanzi, a CAR T cell therapy for relapsed or refractory marginal zone lymphoma. It has a high response rate.
12-05 21:36
MHRA Approves Tisotumab Vedotin For The Treatment Of Cervical Cancer
https://www.gov.uk/government/news/mhra-approves-tisotumab-vedotin-for-the-treatment-of-cervical-cancer
12-02 23:29
FDA Approves Epcoritamab-bysp For Follicular Lymphoma Indications
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-epcoritamab-bysp-follicular-lymphoma-indications
11-18 23:24
Genmab进入收购药物开发商Merus的深入谈判阶段
生物制药公司Genmab （GMAB） 据悉已进入收购荷兰癌症药物开发商Merus （NASDAQ：MRUS） 的深入谈判阶段。今年市值增长60%的Merus预计很快将宣布并购协议。此次收购将增强Genmab的肿瘤产品组合，尽管仍可能出现其他竞标者。 海量资讯、精准解读，尽在新浪财经APP 责任编辑：张俊 SF065
09-29 23:03
Breaking Down Genmab: 4 Analysts Share Their Views
In the preceding three months, 4 analysts have released ratings for Genmab (NAS...
03-12 02:01
William Blair Upgrades Genmab to Outperform
William Blair analyst Matt Phipps upgrades Genmab (NASDAQ:GMAB) from Market Perform to Outperform.
03-11 23:23
Reported Sunday, Genmab's Rinatabart Sesutecan Shows Anti-Tumor Activity In Heavily Pretreated Ovarian And Endometrial Cancer Patients In Phase 1/2 Trial
Treatment with rinatabart sesutecan (Rina-S) showed encouraging response rate in heavily pretreated patients with ovarian cancer in dose expansion cohort Responses with Rina-S were observed across FRα expression
2024-09-16 15:07
Expert Ratings For Genmab
During the last three months, 11 analysts shared their evaluations of Genmab (N...
2024-09-09 22:00
Truist Securities Maintains Buy on Genmab, Lowers Price Target to $50
Truist Securities analyst Asthika Goonewardene maintains Genmab (NASDAQ:GMAB) with a Buy and lowers the price target from $53 to $50.
2024-09-09 21:57
--Morgan Stanley Upgrades Genmab to Equalweight, Price Target is $31
07:49 AM EDT, 09/04/2024 (MT Newswires) -- Price: 27.47, Change: +0.06, Percent Change: +0.22
2024-09-04 19:49
